The results showed that the expression of PRMT6 in glioma of CL and ME subtypes was the highest, significantly higher than that in glioma of PN subtypes, and there was no significant difference in the expression of PRMT6 in glioma of CL and ME subtypes (Fig. 1A, B). This evidence concerns the gene PRMT6 and central nervous system cancer.